Ann: Annual Report to Shareholders, page-57

I appreciate your research. In particular I like a lot your logic, "...So this means FDA actually take in consideration of clinical data from China too right? If that is the case...."

If USA FDA validated Prizma based on data provided from Chinese University, what would the chance be for CHINA CFDA to do the same based on data originated from its own country?